v3.25.2
Fair Value Measurements (Tables)
6 Months Ended 12 Months Ended
Jun. 30, 2025
Dec. 31, 2024
Summary of Financial Instruments Measured at Fair Value On a Recurring Basis   The financial instruments measured at fair value on a recurring basis at December 31, 2023 in the accompanying consolidated balance sheets consist of the following (in thousands):
 
    
Fair value measurement as of December 31, 2023
 
    
Level 1
    
Level 2
    
Level 3
    
Total
 
Assets
           
Certificate of deposit
   $   
— 
     $ 10,151      $   —       $ 10,151  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total
   $ —       $ 10,151      $ —       $ 10,151  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IKENA ONCOLOGY INC    
Summary of Financial Assets Measured at Fair Value
The following tables present information about the Company’s
financial
assets measured or
disclosed
at fair value by level within the fair value hierarchy (in thousands):
 
    
June 30, 2025
    
Quoted Prices
in Active
Markets
(Level 1)
    
Significant
Observable
Inputs
(Level 2)
    
Significant
Unobservable
Inputs
(Level 3)
 
Cash equivalents:
           
Money market funds
   $ 34,334      $ 34,334      $ —       $ —   
Corporate debt securities
     2,399        —         2,399        —   
Marketable securities:
           
Corporate debt securities
     37,352        —         37,352        —   
  
 
 
    
 
 
    
 
 
    
 
 
 
Total assets
   $ 74,085      $ 34,334      $ 39,751      $ —   
  
 
 
    
 
 
    
 
 
    
 
 
 
 
    
December 31,
2024
    
Quoted Prices
in Active
Markets
(Level 1)
    
Significant
Observable
Inputs
(Level 2)
    
Significant
Unobservable
Inputs
(Level 3)
 
Cash equivalents:
           
Money market funds
   $ 34,793      $ 34,793      $ —       $ —   
Marketable securities:
           
U.S. treasury securities
     27,004        —         27,004        —   
Corporate debt securities
     57,989        —         57,989        —   
  
 
 
    
 
 
    
 
 
    
 
 
 
Total assets
   $ 119,786      $ 34,793      $ 84,993      $ —   
  
 
 
    
 
 
    
 
 
    
 
 
 
During the
three
and six months ended June 30, 2025 and 2024, there were no transfers into or out of Level 3.
The following tables present information about the Company’s financial assets measured or disclosed at fair value by level within the fair value hierarchy (in thousands):
 
    
December 31,
2024
    
Quoted
Prices in
Active
Markets
(Level 1)
    
Significant
Observable
Inputs
(Level 2)
    
Significant
Unobservable
Inputs
(Level 3)
 
Cash equivalents:
           
Money market funds
   $ 34,793      $ 34,793      $ —       $   —   
Marketable securities:
           
U.S. treasury securities
     27,004        —         27,004        —   
Corporate debt securities
     57,989        —         57,989        —   
  
 
 
    
 
 
    
 
 
    
 
 
 
Total assets
   $ 119,786      $ 34,793      $ 84,993      $ —   
  
 
 
    
 
 
    
 
 
    
 
 
 
 
    
December 31,
2023
    
Quoted
Prices in
Active
Markets
(Level 1)
    
Significant
Observable
Inputs
(Level 2)
    
Significant
Unobservable
Inputs
(Level 3)
 
Cash equivalents:
           
Money market funds
   $ 53,613      $ 53,613      $ —       $   —   
Marketable securities:
           
Corporate debt securities
     55,571        —         55,571        —   
  
 
 
    
 
 
    
 
 
    
 
 
 
Total assets
   $ 109,184      $ 53,613      $ 55,571      $ —   
  
 
 
    
 
 
    
 
 
    
 
 
 
During the years ended December 31, 2024 and 2023, there were no transfers into or out of Level 3.